Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus TRIPLE SULFOID.
MYTREX F vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic